Immune Checkpoint Inhibitors Emerged As Fundamental Therapeutics For Development Of Cancer Immunotherapy Market Says Kuick Research
Immune Checkpoint Inhibitors Emerged As Fundamental Therapeutics For Development Of Cancer Immunotherapy Market Says Kuick Research
Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights:
• Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion
• Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
• Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
• Biomarkers sourced During clinical Trials
• Biomarkers Insight By Immune Checkpoint Inhibitors Classification
• Insight On Biomarkers Sourced From Trials By Drugs & Indication
• Biomarker Name & Function Insight By Immune Checkpoint Inhibitor Drug
• Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report:
https://www.kuickresearch.com/report-immune-checkpoint-inhibitors-biomarkers
Immune checkpoint inhibitor has emerged out to be cutting edge cancer immunotherapy in last few years. Immune checkpoint inhibitors targeting immune checkpoints, such as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), and programmed death receptors, such as programmed cell death protein 1 (PD-1) has demonstrated huge clinical success in the global market across wide range of cancers. More recently, lymphocyte activation gene-3 (LAG-3) targeting immune checkpoint, Opdualag has also gained approval for the management of melanoma, thus demonstrating huge potential of immune checkpoint inhibitors in the management of cancer. The entrance of these immune checkpoint inhibitors has shown huge clinical success which has propelled the further research and development activities.
The continuous investment in the discovery of novel targets with immune checkpoints has led to identification of several next generation receptors including T cell immunoglobulin and ITM domain (TIGIT), T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3), V-domain Ig suppressor of T-cell activation (VISTA), and others. Amid this, VISTA has become the current focus of research as it is expressed on several cells in tumor microenvironment, giving it broader mechanism of action in comparison to traditional immune checkpoints. The novel receptor has also demonstrated response to those cancers which do not response to PD-1 or CTLA-4 inhibitors. For instance, pancreatic cancer does not respond well to anti–PD-1 or anti–CTLA-4 therapy. However, VISTA-Ig fusion protein inhibits the cytokine production of CD8-positive T cells in the pancreatic TME. Researchers have developed several VISTA inhibitors which are mainly confined to phase-I/II clinical trials. KVA12.1 is a potential best-in-class VISTA blocking immunotherapy that was discovered by Kineta Therapeutics and is being evaluated in phase-I/II clinical trial across solid tumors. It is believed that VISTA will emerge as shining star in cancer immune checkpoint inhibitor market in next 7-10 years.
Apart from monotherapy, the combination of anti-CTLA-4 with anti-PD-1 treatments showed superior efficacy compared to individual administration. The rational of combining multiple checkpoint inhibitors is that they have different mechanisms of action, with anti – CTLA-4 mainly acting in the lymph node compartment which is responsible for restoring the induction and proliferation of activated T cells, and with anti –PD-1 mainly acting at the periphery of tumor site, preventing the neutralization of cytotoxic T cells by PD-L1 expressing tumor and plasmacytoid dendritic cells in the tumor microenvironment (TME).
Although monoclonal antibodies targeting immune checkpoints are currently holding the maximum share in the market, it is believed that bispecific antibodies will make their way in next few years as leading modalities in immune checkpoint inhibitor. Owing to their promising response in combination therapy, researchers have developed several bispecific antibody constructs which target two different immunoreceptor, thus reducing the overall cost of therapy for patients. In comparison to monoclonal antibodies, bispecific antibodies have smaller size and better penetration to blood brain barrier, which also favors their development among pharmaceutical market. It is expected that several bispecific antibody will gain entry into the market in the forthcoming years which are believed to transform the global immune checkpoint inhibitor market by showing high adoption rates.
Global Combination Cancer Immunotherapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
• Global & Regional Combination Cancer Immunotherapy Market Insight Till 2028
• Combination Cancer Immunotherapy Market Opportunity: > USD 15 Billion
• Combination Cancer Immunotherapy Market By 15 Different Cancers
• Insight On Clinically & Commercially Approved Cancer Immunotherapy Combinations
• Patent, Price & Dosage Analysis On Approved Combination Drugs
• Global & Regional Sales Insights On Approved Combination Drugs Till 2028
• Insight on 600 Combination Cancer Immunotherapy Drugs In Clinical Trials
• Insight on 45 Combination Cancer Immunotherapy Drugs Commercially Approved In Market
• Clinical Trials & Patent Insight By Company, Country, Indication & Phase
Download Report:
https://www.kuickresearch.com/report-combination-cancer-therapy-market
Despite their promising success in the market, these are associated with few challenges which need to be overcome. Immune checkpoint inhibitors have shown to be beneficial in some patients only and therefore, research studies related to immune checkpoint inhibitors from past few years have inclined to the identification of novel biomarkers which is a characteristic that can be measured as an indicator of normal or pathogenic biological processes or of responses to an exposure or intervention. The rising pipeline of immune checkpoint inhibitors associated with the unmet need for development of biomarker has encouraged pharmaceutical companies to actively invest in this segment.
Recently researchers at Mount Sinai have designed liquid biopsy test which can be predictor of whether cancer immunotherapy will work for a patient with lung cancer than an invasive tumor biopsy technique. The study has revealed that testing the blood of lung cancer patients for the PD-L1 biomarker gave more accurate predictions of the response and survival for patients with lung cancer than testing for PD-L1 in tissue from lung cancer biopsies, current standard of care. In addition to this, EV-PD-L1 came from extracellular vesicles, which are shed by tumor cells. Therefore, a decline in PD-L1 expression in extracellular vesicles in blood could therefore become a useful test to predict which patients with non-small-cell lung cancer could benefit from immunotherapy.
Further, the introduction of advanced technologies like artificial intelligence is also expected to bring significant changes in drug development process, conducting clinical trials, and identifying novel biomarkers. For instance, Lunit has also developed Lunit’s AI biomarker, Lunit SCOPE IO which has shown encouraging results in predicting clinical outcomes of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC). In addition to this, the company has also developed deep learning (DL)-based HE image analyzer called Lunit SCOPE that identifies and quantifies various histological parameters from HE-stained whole slide images (WSIs). Studies have shown that Lunit SCOPE was able to predict an abundance of cancer associated stroma in pancreatic adenocarcinoma as well as tumor infiltrating lymphocytes in immunogenic tumors such as renal carcinoma, melanoma, and urothelial cancer.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com